PHILADELPHIA, PA — Context Therapeutics Inc. (Nasdaq: CNTX) announced a poster regarding the Company’s preclinical asset, CTIM-76, a Claudin 6 x CD3 bispecific antibody will be presented at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting taking place November 3-5, 2023, at the San Diego Convention Center in San Diego, CA.
Details of the presentation are as follows:
Title: Development of CTIM-76, a highly specific Claudin 6 bispecific antibody
Abstract Number: 1183
Presenter: Joseph Rucker, Ph.D., Integral Molecular
Date and Time: Friday, November 3, 2023, 9:00 a.m. – 7:00 p.m. PT
Location: Exhibit Halls A and B1, San Diego Convention Center
For more information and to view the abstract, visit the SITC 38th Annual Meeting website.